The methylation chemistry behind the stack

Every time NAD+ is consumed in a cell - by sirtuins doing their deacetylation work, by PARPs responding to DNA damage, by CD38 in immune signalling - the resulting nicotinamide must be detoxified. The body achieves this through methylation: enzymatic transfer of a methyl group (CH3-) onto nicotinamide to produce N-methylnicotinamide (MNA), which is then excreted in urine.

The methyl group for this reaction comes from S-adenosylmethionine (SAMe), the universal methyl donor in the body’s methylation economy. SAMe is consumed in the reaction and must be regenerated from methionine, with help from folate (B9), B12, choline, and betaine (TMG) feeding into the methionine cycle.

The mechanistic concern with high-dose NMN is straightforward: more NMN → more NAD+ turnover → more nicotinamide → more methylation demand → more SAMe consumed. If the methylation cycle’s regeneration capacity is overwhelmed, the body’s broader methylation economy (DNA methylation, neurotransmitter synthesis, phospholipid synthesis, creatine synthesis) could theoretically suffer.

This is the rationale Sinclair and several other longevity scientists have articulated for adding TMG (or folate + B12 + choline) when supplementing NAD+ precursors at higher doses.

Quantifying the depletion at typical NMN doses

The published quantitative data on actual SAMe consumption from NMN supplementation in humans is limited. We can estimate from biochemistry:

  • 250mg NMN yields roughly 220mg of nicotinamide stoichiometrically.
  • Methylating 220mg of nicotinamide consumes ~270mg SAMe (1:1 molar with adjustment for molecular weights).
  • A typical adult Western diet provides 7-30 mmol/day of methyl-donor capacity (folate, choline, betaine combined). 270mg SAMe consumed represents under 5% of typical daily flux.
  • At 1g NMN/day, the load rises to ~20% of typical daily methyl flux - meaningful but still well within physiological capacity for most adults with adequate diet.

This back-of-envelope calculation suggests the methyl-pool concern is real but modest at clinical NMN doses. It is more clinically relevant in:

  • People on very high NMN doses (>1g/day).
  • People with low dietary intake of folate, B12, choline, betaine.
  • People with MTHFR genetic variants (C677T, A1298C) reducing methyl recharging efficiency.
  • People with elevated baseline homocysteine on bloodwork.
  • People with conditions affecting methylation: alcohol use, certain medications (methotrexate, anticonvulsants).

For a healthy Malaysian adult on 250mg NMN/day eating a reasonable diet, the methyl-pool depletion is unlikely to be clinically meaningful. For higher doses or stressed populations, TMG is reasonable insurance.

TMG’s independent cardiovascular evidence

TMG (trimethylglycine, also called betaine) has its own evidence base separate from NMN context. The cardiovascular literature is the strongest component:

Homocysteine reduction. Multiple randomised trials at 3-6g/day TMG show consistent dose-dependent reduction in plasma homocysteine. Effect size is meaningful - 10-20% reduction depending on baseline level.

Cardiovascular hard endpoints. Whether homocysteine reduction translates to reduced cardiovascular events is contested. Some trials negative, others suggestive. The mechanistic rationale (homocysteine as endothelial toxin) is plausible; the clinical translation is incomplete.

Liver function. TMG has documented benefit in non-alcoholic fatty liver disease, with multiple studies showing improvement in liver enzymes and fat content at 1-3g/day.

Athletic performance. Smaller trials suggest TMG 2.5g/day may improve power output and body composition in resistance-trained adults. Effect size modest.

For a Malaysian buyer, the cardiovascular and liver function evidence stands on its own; the methyl-pool support for NMN is a secondary use case.

Direct evidence on the NMN + TMG combination

The honest summary: there is no published large randomised trial specifically on the NMN + TMG combination versus NMN alone or placebo. The Sinclair-publicised stack is mechanistic reasoning plus the components’ individual evidence, not a head-to-head study.

What we do have:

  • Igarashi 2022 NMN trial - participants were not specifically supplemented with TMG; the published efficacy signal at 250mg/day NMN morning dose is therefore “without TMG.”
  • Multiple TMG cardiovascular trials in non-NMN context.
  • No specific trial of NMN+TMG vs NMN alone for any NAD+/longevity outcome.

A user adding TMG to their NMN protocol is operating on mechanism plus general TMG evidence, not on direct combination evidence. This is a reasonable basis given the cost (RM 30-90 per month additional) and tolerability profile, but it is important to be honest about the evidence shape.

Practical protocol for Malaysian buyers

If you choose to add TMG to your NMN protocol:

Dose: 500-1000mg TMG/day. This is the methyl-pool support range, well below the 3-6g cardiovascular range. Sinclair takes 500-1000mg.

Timing: Often split between morning (with NMN) and evening, or taken once with the larger meal. Timing flexibility is high; food coadministration improves tolerability.

Form: Trimethylglycine or betaine anhydrous (the same molecule by different names) at 500-1000mg per capsule from reputable supplement brands. Some longevity-stack products combine NMN+TMG in single capsules.

Monitoring: If concerned about methylation status, consider baseline + 12-week homocysteine bloodwork. Most healthy adults do not need this routinely; it is informative if you have a specific reason (cardiovascular history, MTHFR known variant, elevated baseline).

Stop or adjust: Reduce dose if you experience GI upset (loose stools, uncommon at 500-1000mg). Pause for kidney disease, pregnancy, or before any planned procedure.

Alternative path: A folate + B12 supplement provides similar methylation support via a different pathway. Many longevity stacks include both. For most adults, B-complex covers folate + B12; TMG adds the betaine arm. Cost is similar.

When TMG may not be needed

The case for TMG weakens in:

  • NMN doses ≤250mg/day. Methyl drain is small; dietary methyl donors easily cover.
  • Methyl-rich diets. Regular consumption of beetroot, spinach, quinoa, eggs, liver, salmon, wheat germ provides substantial dietary methyl support.
  • Already on B-complex or folate supplementation. Methylation pathway is supported through alternative arm.
  • Normal homocysteine on recent bloodwork. No biomarker signal of methylation stress.

For Malaysian buyers, dietary methyl donors are accessible: beetroot at supermarkets (Cold Storage, Jaya Grocer), spinach (sayur kangkung as bayam alternative is also methyl-rich), eggs (ubiquitous), wheat germ (health food sections of larger supermarkets). A diet with these foods plus 250mg NMN/day rarely benefits from added TMG.

Bottom line

The methyl-pool depletion concern from high-dose NMN is theoretically real, mechanistically defensible, and quantitatively modest at typical clinical doses. TMG is a cheap (RM 30-90 per month) and well-tolerated way to address it for users on higher NMN doses or with stressed methyl pools. Direct RCT evidence on the NMN+TMG combination specifically is thin; the rationale rests on mechanism plus TMG’s independent cardiovascular and liver-function evidence base.

For a Malaysian buyer at 250mg NMN/day with a reasonable diet, TMG is optional and adds modest insurance. For buyers at 500mg-1g NMN/day, TMG is more strongly defensible. For buyers with elevated homocysteine, MTHFR variants, or low-betaine diets, TMG addition is well-justified independent of NMN context.